Suppr超能文献

可乐定对人体血浆中去甲肾上腺素出现率的剂量依赖性抑制作用。

Dose-dependent suppression of norepinephrine appearance rate in plasma by clonidine in man.

作者信息

Veith R C, Best J D, Halter J B

出版信息

J Clin Endocrinol Metab. 1984 Jul;59(1):151-5. doi: 10.1210/jcem-59-1-151.

Abstract

Clonidine is an alpha 2-receptor agonist which lowers both blood pressure and plasma norepinephrine (NE) levels in man. To determine whether the clonidine-induced fall in plasma NE is due to decreased NE appearance into plasma or increased NE clearance from plasma, NE infusions [( 3H]NE; 15 microCi/m2 bolus and 0.35 microCi/m2 X min infusion) were performed in 10 normal subjects, aged 25-56 yr. Arterialized plasma samples were obtained for measurements of steady state [3H]NE specific activity and plasma NE to allow calculation of plasma NE appearance rate and NE clearance before and 120-140 min after 1.5 and 5.0 micrograms/kg oral clonidine. Using an identical protocol, responses were compared in 4 subjects after placebo administration. Clonidine produced a dose-related reduction in mean arterial blood pressure, but no significant change in heart rate. The basal supine plasma NE concentration of 204 +/- 21 pg/ml (mean +/- SEM) fell by 27% (P less than 0.02) after low dose clonidine and by 51% (P less than 0.001) after high dose clonidine. There was no change in plasma epinephrine levels. The basal plasma NE appearance rate of 0.25 +/- 0.03 microgram/m2 X min was reduced by 32% (P less than 0.01) after low dose clonidine and by 52% (P less than 0.001) after high dose clonidine. The basal plasma NE clearance of 1.2 +/- 0.08 liters/m2 X min was unchanged after clonidine treatment. There was no change in mean plasma NE levels, plasma NE appearance rate, or mean arterial pressure after placebo administration. These findings demonstrate that the clonidine-induced fall in plasma NE levels is due to a dose-dependent suppression of plasma NE appearance rate and provide evidence for alpha 2-adrenergic inhibition of sympathetic nervous system activity in normotensive subjects.

摘要

可乐定是一种α2受体激动剂,可降低人体血压和血浆去甲肾上腺素(NE)水平。为了确定可乐定引起的血浆NE下降是由于血浆中NE生成减少还是血浆中NE清除增加,对10名年龄在25 - 56岁的正常受试者进行了NE输注([3H]NE;15微居里/平方米推注和0.35微居里/平方米×分钟输注)。采集动脉化血浆样本,用于测量稳态[3H]NE比活性和血浆NE,以便在口服1.5和5.0微克/千克可乐定前及之后120 - 140分钟计算血浆NE生成率和NE清除率。采用相同方案,对4名服用安慰剂后的受试者的反应进行了比较。可乐定使平均动脉血压呈剂量依赖性降低,但心率无显著变化。基础仰卧位血浆NE浓度为204±21皮克/毫升(平均值±标准误),低剂量可乐定后下降27%(P<0.02),高剂量可乐定后下降51%(P<0.001)。血浆肾上腺素水平无变化。基础血浆NE生成率为0.25±0.03微克/平方米×分钟,低剂量可乐定后降低32%(P<0.01),高剂量可乐定后降低52%(P<0.001)。可乐定治疗后,基础血浆NE清除率为1.2±0.08升/平方米×分钟,无变化。服用安慰剂后,平均血浆NE水平、血浆NE生成率或平均动脉血压均无变化。这些发现表明,可乐定引起的血浆NE水平下降是由于血浆NE生成率的剂量依赖性抑制,并为正常血压受试者中α2肾上腺素能抑制交感神经系统活性提供了证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验